EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss

Minas Nalbandian, Jameel Lone, Emmeran Le Moal, Ireh Kim, Kaitlin Jeuris, Yutong Kelly Li, Peggy Kraft, Meng Zhao, Kassie Koleckar, Zeyuan Zhang, Katrin J Svensson iD, Helen M Blau

Proceedings of the National Academy of Sciences · 09.06.2026 · 123 (23)

DOI: 10.1073/pnas.2606533123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 02.06.2026. Verfasst von Minas Nalbandian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford School of Medicine, Stanford, CA 94305. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Hydroxyprostaglandin Dehydrogenases, Muscle Strength. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Milky Way Research Foundation (MWRF), SU | SOM | Stanford Cardiovascular Institute, School of Medicine, Stanford University (CVI), SU | Stanford Bio-X.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists, including long-acting semaglutide, are transformative anti-obesity therapies. However, emerging evidence indicates that weight loss may come at the expense of skeletal muscle mass, a tissue essential for mobility, metabolic regulation, and overall health. Here, we show that inhibition of the gerozyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a prostaglandin-degrading enzyme that increases with injury and aging, improves muscle repair and strength recovery in the presence of semaglutide. In a high fat diet-induced mouse model of obesity, semaglutide alone caused significant loss of muscle mass, while preserving contractile function. Following injury, obese mice exhibited pathological calcifications previously reported for the heritable myopathy, Duchenne Muscular Dystrophy. Semaglutide had both beneficial and deleterious effects, reducing calcific remodeling, but causing reduced regenerated myofiber sizes. This impaired regenerative myofiber growth in semaglutide-treated mice was surmounted by cotreatment with a 15-PGDH inhibitor (PGDHi), which stimulated muscle stem cell function and myofiber growth, leading to enhanced strength. Importantly, PGDHi synergizes with semaglutide to boost postinjury muscle quality and muscle force without compromising weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHydroxyprostaglandin DehydrogenasesMuscle StrengthMuscle, SkeletalWeight LossAnimalsMaleMiceDiet, High-FatGlucagon-Like Peptide-1 ReceptorMice, Inbred C57BLObesitySemaglutideAnti-Obesity Agents

Stichwörter der Autor:innen

15-PGDH (gerozyme)GLP-1 receptor agonistmuscle stem cellssemaglutideskeletal muscle regeneration

Substanzen

15-hydroxyprostaglandin dehydrogenaseGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHydroxyprostaglandin DehydrogenasesSemaglutideAnti-Obesity Agents

Autor:innen und Institutionen

  • Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford School of Medicine, Stanford, CA 94305.
  • Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.
  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305.
  • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305.
  • Department of Animal Science, University of California, Davis, CA 95616.
  • Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA 94305.

ORCID-Profile: Katrin J Svensson

Förderung

  • Milky Way Research Foundation (MWRF)
  • SU | SOM | Stanford Cardiovascular Institute, School of Medicine, Stanford University (CVI)
  • SU | Stanford Bio-X
  • HHS | NIH | National Institute on Aging (NIA)
  • American Heart Association (AHA)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Zitieren

APA

Nalbandian, M., Lone, J., Le Moal, E., Kim, I., Jeuris, K., Li, Y. K., Kraft, P., Zhao, M., Koleckar, K., Zhang, Z., Svensson, K. J., & Blau, H. M. (2026). 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss. Proceedings of the National Academy of Sciences, 123(23). https://doi.org/10.1073/pnas.2606533123

Vancouver

Nalbandian M, Lone J, Le Moal E, Kim I, Jeuris K, Li YK, et al. 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss. Proceedings of the National Academy of Sciences. 2026;123(23). doi:10.1073/pnas.2606533123

BibTeX
@article{Nalbandian2026,
  author = {Nalbandian, Minas and Lone, Jameel and Le Moal, Emmeran and Kim, Ireh and Jeuris, Kaitlin and Li, Yutong Kelly and Kraft, Peggy and Zhao, Meng and Koleckar, Kassie and Zhang, Zeyuan and Svensson, Katrin J and Blau, Helen M},
  title = {15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {23},
  doi = {10.1073/pnas.2606533123}
}
Kostenlos starten →